dalcetrapib and Prediabetic-State

Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome.. At baseline, 10,645 patients (67% of the trial cohort) did not have diabetes. During a median follow-up of 30 months, incident diabetes was identified in 403 of 5,326 patients (7.6%) assigned to dalcetrapib and in 516 of 5,319 (9.7%) assigned to placebo, corresponding to absolute risk reduction of 2.1%, hazard ratio of 0.77 (95% CI 0.68-0.88;. In patients with a recent acute coronary syndrome, incident diabetes is common and is reduced substantially by treatment with dalcetrapib.

Topics: Acute Coronary Syndrome; Aged; Amides; Anticholesteremic Agents; Blood Glucose; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Esters; Female; Humans; Incidence; Male; Middle Aged; Prediabetic State; Risk Factors; Risk Reduction Behavior; Sulfhydryl Compounds